Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

Publication

Article

June 11, 2007

CURE

Summer 2007
Volume6
Issue 4

Treating Tobacco-Related Lung Cancer

Author(s):

Elizabeth Whittington

Therapies that preferentially target lung cancers harboring certain EGFR mutations can be effective in some lung cancers in never-smokers.

Therapies that preferentially target lung cancers harboring certain EGFR mutations can be effective in some lung cancers in never-smokers. And while these certain therapies may not work as well in lung cancers in smokers and former smokers, these patients may respond better to therapies that target other mutations and pathways.

Tumors release a protein called VEGF, or vascular endothelial growth factor, which signals the growth of blood vessels to feed the tumor, a process called angiogenesis. Avastin® (bevacizumab), a drug approved for non-small cell lung cancer and metastatic colorectal cancer, inhibits angiogenesis by binding to VEGF, thus slowing tumor growth. In a phase III study of close to 900 lung cancer patients, Avastin was found to improve median overall survival by 25 percent when combined with chemotherapy. Patients who received Avastin with chemotherapy had a median survival of 12.3 months compared with 10.3 months in patients treated with only chemotherapy. Side effects seen in the trial included low white blood cell count, fatigue, and high blood pressure.

In another study published in 2005, researchers combined Avastin with Tarceva to treat current and former smokers as well as patients who never smoked. Two of the nine patients (22.2 percent) who had never smoked had a partial response compared with six of 31 former or current smokers (19.4 percent). Although the effect was similar for both groups and the combination appears effective in either population, researchers caution more research is needed because of the small number of patients treated in this early-phase clinical trial.

Other treatment options include surgery if the cancer hasn’t spread, radiation to the chest wall, and chemotherapy with agents such as Taxol, Gemzar® (gemcitabine), and cisplatin. Studies show smokers who stop smoking during chemotherapy respond better than those who continue to use tobacco. Researchers believe this effect may be because of the nicotine in tobacco. While not a carcinogen itself, nicotine may promote tumor growth by influencing certain biological pathways.

Research suggests never-smokers respond better to chemotherapy and have improved survival when compared with former and current smokers, but the outcome may be because never-smokers have less genetic damage or mutations from smoking, fewer health problems caused by smoking, and better lung function overall. Smokers and former smokers also have a higher risk of developing hard-to-treat lung cancers, such as squamous cell and small cell lung cancers, when compared with never-smokers, who are typically diagnosed with adenocarcinoma, a type of non-small cell lung cancer.

Articles in this issue

How to Find Help
Job Transitions, Insurance Change
Medicare Coverage for Colon Cancer Screenings
Noting Group Differences
The Journey of Cancer Survivorship
Beauty Shopping
Pregnancy After Cancer
Fast Facts: Richard Roundtree
Portal Authority
Precious Tumor
Surviving "Survivor" Stereotypes
The Secret of Caregivers
Surgeons and Robots
A Hole In The World
Making the Most of a Portal

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Content
Advertisement
Dr. Lorenzo Cohen and Alison Jefferies discuss small yet meaningful changes that patients can make to their home environment to foster a sense of wellness: © stock.adobe.com.
August 1st 2025

Meaningful Changes to Reduce Environmental Toxicities

Ryan Scott
Dr. Lorenzo Cohen and Alison Jefferies discuss small yet meaningful changes that patients can make to their home environment to foster a sense of wellness.
TIL therapy is on the rise in melanoma, with potential for other tumor types.
August 1st 2025

Empowering the Immune System

Darlene Dobkowski, MA
TIL therapy is on the rise in melanoma, with potential for other tumor types.
Cancer touches everyone — cutting across religion, race, ethnicity, sexual orientation and socioeconomic status: © stock.adobe.com.
August 1st 2025

Funding for Cancer Research: Hope in a State of Fear

Dr. Joshua K. Sabari
Cancer is nonpartisan. It touches everyone — cutting across religion, race, ethnicity, sexual orientation and socioeconomic status.
A significant development in the treatment of advanced melanoma has recently emerged: © stock.adobe.com.
August 1st 2025

A New Frontier in Melanoma Treatment

Mike Hennessy Jr.
A significant development in the treatment of advanced melanoma has recently emerged: tumor-infiltrating lymphocyte (TIL) therapy.
Image of hand.
August 1st 2025

Oncology Nurse Amanda Snyder Turns Personal Experience Into Advocacy

Jeanine Pronio
Amanda Snyder, a cancer survivor, became an oncology nurse to provide support she once lacked, now leading innovative therapies for patients.
How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.
August 1st 2025

Utilizing AI in Prostate Cancer Care and Management

Alex Biese
How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.
Related Content
Advertisement
Dr. Lorenzo Cohen and Alison Jefferies discuss small yet meaningful changes that patients can make to their home environment to foster a sense of wellness: © stock.adobe.com.
August 1st 2025

Meaningful Changes to Reduce Environmental Toxicities

Ryan Scott
Dr. Lorenzo Cohen and Alison Jefferies discuss small yet meaningful changes that patients can make to their home environment to foster a sense of wellness.
TIL therapy is on the rise in melanoma, with potential for other tumor types.
August 1st 2025

Empowering the Immune System

Darlene Dobkowski, MA
TIL therapy is on the rise in melanoma, with potential for other tumor types.
Cancer touches everyone — cutting across religion, race, ethnicity, sexual orientation and socioeconomic status: © stock.adobe.com.
August 1st 2025

Funding for Cancer Research: Hope in a State of Fear

Dr. Joshua K. Sabari
Cancer is nonpartisan. It touches everyone — cutting across religion, race, ethnicity, sexual orientation and socioeconomic status.
A significant development in the treatment of advanced melanoma has recently emerged: © stock.adobe.com.
August 1st 2025

A New Frontier in Melanoma Treatment

Mike Hennessy Jr.
A significant development in the treatment of advanced melanoma has recently emerged: tumor-infiltrating lymphocyte (TIL) therapy.
Image of hand.
August 1st 2025

Oncology Nurse Amanda Snyder Turns Personal Experience Into Advocacy

Jeanine Pronio
Amanda Snyder, a cancer survivor, became an oncology nurse to provide support she once lacked, now leading innovative therapies for patients.
How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.
August 1st 2025

Utilizing AI in Prostate Cancer Care and Management

Alex Biese
How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.